甲磺酸去铁胺治疗骨质疏松的疗效及其对患者骨代谢指标的影响

目的：探讨甲磺酸去铁胺治疗骨质疏松的治疗及其对患者骨代谢指标的影响。方法采用随机数字法将我院2013年1月在2015年6月就诊的70例老年女性骨质疏松患者分为观察组与对照组，每组各35例，对照组采取常规治疗，观察组除常规治疗外加以甲磺酸去铁胺输注，总疗程均为12周，比较两组患者的临床疗效、不良反应、治疗前后骨密度、骨代谢指标及氧化应激指标的差异。结果观察组患者的治疗总有效率为100.0%，明显高于对照组的85.7%，差异有统计学意义(P<0.05)；两组患者治疗后的腰椎正位、股骨颈骨密度较治疗前均明显上升，且观察组上升幅度明显大于对照组，差异均有统计学意义(P<0.05)；观察组患者治疗的血清骨钙素(OC)、甲状旁腺激素(PTH)、血清I型胶原C端肽(CTX-I)、血清铁蛋白水平分别为(6.40±3.82) ng/mL、(45.82±2.68) pg/mL、(0.22±0.20) ng/mL、(60.48±20.36) ng/mL，均明显低于对照组的(8.62±3.46) ng/mL、(55.13±2.77) pg/mL、(0.34±0.25) ng/mL、(260.12±52.17) ng/mL，差异均有统计学意义(P<0.05)。观察组治疗后的丙二醛(MDA)为(6.82±0.77) nmol/L，低于对照组的(8.13±0.81) nmol/L，超氧化物岐化酶(SOD)为(8.78±0.76) U/mL，高于对照组的(7.00±0.78）U/mL，差异均有统计学意义(P<0.05)。治疗过程中两组患者均无明显不良反应发生。结论老年女性骨质疏松患者多存在铁过载现象，加以甲磺酸去铁胺降铁治疗能明显提高骨密度，改善骨代谢指标，其可能是通过改善机体氧化应激水平发挥作用。

Effect of deferoxamine mesylate in the treatment of osteoporosis and its influence on bone metabolism indexes in the patients

Objective To explore the curative effect of deferoxamine mesylate in the treatment of osteoporosis and its influence on bone metabolism indexes in the patients. Methods Seventy elderly female patients with osteoporo-sis who treated in our hospital from January 2013 to June 2015 were divided into the observation group and the control group according to the random number table, with 35 patients in each group. The patients in the control group were treat-ed with routine therapy, and those in observation group were treated with deferoxamine mesylate injection on the basis of the control group, with the total course of treatment for 12 weeks. The difference of clinical effect, adverse reactions, bone mineral density before and after treatment, bone metabolism indexes and oxidative stress indexes were compared between the two groups. Results The total effective rate in the observation group (100.0%) was significantly higher than that in the control group of 85.7%(P<0.05). After treatment, bone mineral density of lumbar normotopia and femo-ral neck of both groups was significantly increased, and the rising range in observation group was higher than that in control group (P<0.05). After treatment, the levels of serum osteocalcin (OC), parathyroid hormone (PTH), serum type I collagen C-terminal peptide (CTX-I) and serum ferritin in the observation group were significantly lower than those in the control group, with (6.40±3.82) ng/mL vs (8.62±3.46) ng/mL, (45.82±2.68) pg/mL vs (55.13±2.77) pg/mL, (0.22±0.20) ng/mL vs (0.34±0.25) ng/mL, (60.48±20.36) ng/mL vs (260.12±52.17) ng/mL, P<0.05. After treatment, malo-ndialdehyde (MDA) in observation group was significantly lower than that in control group with (6.82 ± 0.77) nmol/L vs (8.13±0.81) nmol/L, while superoxide dismutase (SOD) in observation group was higher than that in control group with (8.78 ± 0.76) U/mL vs (7.00 ± 0.78) U/mL, P<0.05. There were no obvious adverse reactions in both groups during the treatment. Conclusion Most elderly female patients with osteoporosis have iron overload phenomenon. Using deferox-amine mesylate therapy can significantly improve the bone mineral density and improve bone metabolism indexes. It may play a role by improving the level of oxidative stress in the body.